Recordati Industria Chimica e Farmaceutica

RECORDATI: PUBLICATION OF THE INTERIM REPORT AS AT 31.03.2025 AND OF THE MINUTES OF THE SHAREHOLDERS' MEETING DATED 29.04.2025

Milan, 12 th May 2025 – Please be informed that the Interim Report as at 31st March 2025, representing additional voluntary financial reporting, approved by the Board of Directors on 8 th May 2025, as per the press release issued on the same date, today has been made available to the public at the Company's registered office, on the Company's website and on the "" storage mechanism.

Please also be informed that, pursuant to Article 125-quater of the Legislative Decree 58/98, the minutes of the Ordinary General Meeting of the Shareholders held on 29th April 2025 have been made available today to the public at the Company's registered office, on the Company's website and on the storage mechanism.

Recordati is an international pharmaceutical group listed on the Italian Stock Exchange (XMIL: REC), with roots dating back to a family-run pharmacy in Northern Italy in the 1920s. We are uniquely structured to provide treatments across specialty and primary care, and rare diseases. Our fully integrated operations span clinical development, chemical and finished product manufacturing, commercialization and licensing. We operate in approximately 150 countries across EMEA, the Americas and APAC with over 4,580 employees. We believe that health is a fundamental right, not a privilege. Today, our purpose of "unlocking the full potential of life" aims at empowering individuals to live life to the fullest, whether addressing common health challenges or the rarest.

Investor Relations

Eugenia Litz +44 7824 394 750 [email protected] Gianluca Saletta +39 348 979 4876 [email protected]

Media Relations

ICR Healthcare US: Alexis Feinberg +1 203 939 2225 [email protected] UK, Europe & Rest of World: Jessica Hodgson +44 7561 424 788 [email protected]